Centre Hospitalier De Laval
- Address
- lock Available on a paid plan
Centre Hospitalier De Laval - Respiratory Medicine Research
Centre Hospitalier De Laval participates in advanced clinical research focused on respiratory diseases, with particular expertise in investigating novel therapeutic approaches for chronic pulmonary conditions. The center contributes to pivotal studies examining innovative pharmacological interventions and their impact on patient outcomes.
- Chronic Obstructive Pulmonary Disease (COPD) management and treatment optimization
- Combination inhaler therapies and bronchodilator research
- Cardiopulmonary outcomes assessment in respiratory disease
The center's research portfolio includes investigations of triple therapy combinations utilizing budesonide, glycopyrronium, and formoterol fumarate delivered via metered-dose inhalers. These studies evaluate the effectiveness of combining inhaled corticosteroids with dual bronchodilators in preventing severe cardiopulmonary complications in COPD patients, contributing valuable evidence to optimize therapeutic strategies for this progressive respiratory condition.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier De Laval
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Discontinuation of Beta-Blockers in Heart Failure Patients with Recovered Left Ventricular Ejection Fraction: A Non-Inferiority Study | Assistance Publique Hopitaux De Paris | Phase III | Recruiting | Feb 2025 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ace Inhibitors, Plain | 1 | Unknown | 2025-02-11 | 2025-02-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.